For the quarter ending 2025-09-30, CNSP has $11,869,258 in assets. $1,959,117 in debts. $9,864,087 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 9,864,087 | 12,129,873 | ||
| Deferred offering costs | 43,700 | 14,173 | ||
| Subscription receivable | 0 | 0 | ||
| Prepaid expenses and other current assets | 1,483,948 | 1,993,774 | ||
| Total current assets | 11,391,735 | 14,137,820 | ||
| Prepaid expenses, net of current portion | 474,416 | 366,251 | ||
| Property and equipment, net | 3,107 | 3,804 | ||
| Total noncurrent assets | 477,523 | 370,055 | ||
| Total assets | 11,869,258 | 14,507,875 | ||
| Accounts payable and accrued expenses | 1,928,324 | 1,261,123 | ||
| Notes payable | 30,793 | 121,767 | ||
| Total current liabilities | 1,959,117 | 1,382,890 | ||
| Total liabilities | 1,959,117 | 1,382,890 | ||
| Common stock, 0.001 par value, 25,000,000 shares authorized and 574,580 and 117,796 shares issued and outstanding, respectively | 574 | 504 | ||
| Additional paid-in capital | 104,229,033 | 104,225,466 | ||
| Accumulated deficit | -94,319,466 | -91,100,985 | ||
| Total stockholders' equity (deficit) | 9,910,141 | 13,124,985 | ||
| Total liabilities and stockholders' equity (deficit) | 11,869,258 | 14,507,875 | ||
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)